Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;32(2):104-111.
doi: 10.2337/ds18-0005.

Insulin Initiation and Titration in Patients With Type 2 Diabetes

Ji Chun  1 , Jodi Strong  2 , Scott Urquhart  3
Affiliations

Insulin Initiation and Titration in Patients With Type 2 Diabetes

Ji Chun et al. Diabetes Spectr. 2019 May.

Abstract

Insulin initiation and titration can be challenging for many primary care providers who are involved in the treatment of patients with type 2 diabetes. Despite the introduction of advanced insulin analogs and improvements in insulin delivery devices, many patients with type 2 diabetes continue to experience suboptimal glycemic control. With an increasing number of treatment options available, type 2 diabetes management is moving away from a "one-size-fits-all" approach and toward individualized treatment regimens based on particular patient needs. Given this, nurse practitioners, physician assistants, pharmacists, and certified diabetes educators are becoming increasingly valuable resources in busy primary care practices.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.
ADA-recommended approach to initiating and titrating insulin in type 2 diabetes. Reprinted with permission from ref. 37; adapted with permission from ref. 61. ©2015 American Diabetes Association. FBG, fasting blood glucose; GLP-1RA, GLP-1 receptor agonist; hypo, hypoglycemia.
FIGURE 2.
FIGURE 2.
AACE-recommended approach to initiating and titrating insulin in type 2 diabetes. Reprinted with permission from ref. 38. ©2018 American Association of Clinical Endocrinologists. BG, blood glucose; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1 RA, GLP-1 receptor agonist; SGLT-2i, sodium–glucose cotransporter 2 inhibitor.
See this image and copyright information in PMC

References

    1. Lovre D, Fonseca V. Benefits of timely basal insulin control in patients with type 2 diabetes. J Diabetes Complications 2015;29:295–301 - PubMed
    1. Peyrot M, Rubin RR, Lauritzen T, et al. , on behalf of the International DAWN Advisory Board. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs study (DAWN). Diabetes Care 2005;28:2673–2679 - PubMed
    1. Rubin RR, Peyrot M, Kruger DF, Travis LB. Barriers to insulin injection therapy: patient and health care provider perspectives. Diabetes Educ 2009;35:1014–1022 - PubMed
    1. Dailey G, Aurand L, Stewart J, Ameer B, Zhou R. Comparison of three algorithms for initiation and titration of insulin glargine in insulin-naive patients with type 2 diabetes mellitus. J Diabetes 2014;6:176–183 - PubMed
    1. Phillips LS, Branch WT, Cook CB, et al. . Clinical inertia. Ann Intern Med 2001;135:825–834 - PubMed